FYI-I checked with an asset management company that is invested in CMTR and received the following response. See Dan, some of us do care.
Subj: Re: Chemtrak
Date: 96-12-12 16:34:44 EST
From: craig@assetman.com (Craig Taylor)
To: HartLar@aol.com
Reply to: RE>Chemtrak
Yes, we have an investment in Chemtrak. We think it is worth seeing how the H
pylori and HIV tests roll out, given the low valuation of the company.
cct
--------------------------------------
Date: 12/10/96 6:56 PM
To: Craig Taylor
From: HartLar@aol.com
I was curious to know if you still have an investment in Chemtrak and if so
what your companies thoughts were on continued investment. Any response
would be helpful. Thanks.
Info on the Asset Management Company is as follows:
Asset Management Company
2275 East Bayshore Road, Suite 150
Palo Alto,California 94303 U.S.A.
Phone: 415-494-7400 Fax: 415-856-1826 E-mail: craig@assetman.com
Industry: Service
Segment: Venture Capital
Profile
Asset Management Company is a venture capital firm emphasizing involvement in seed or
start-up companies in the physical, computer and biological sciences.
The Company was founded in 1967 and has been engaged almost exclusively in venture capital
investment. The firm has four partnerships under management, totaling about $150 million.
Venture investments in the biosciences field include Abaxis, Adeza Biomedical, Amgen, Applied
Biosystems, Biometric Imaging, Chemtrak, CV Therapeutics, Fusion Medical Technologies,
Genta, Hybritech, IDEC Pharmaceuticals, InSearch, Lumisys, Mesagnestics, Metra Biosystems,
Molecular Dynamics, Neocrin, Pharmacyclics and Telor Ophthalmic.
The general partners are experienced professionals in the field of entrepreneurial venture capital.
Frequently they join the board of directors after an investment is made.
Asset Management concentrates on investments in the West and Northeast region and seeks to
invest a minimum of $1,000,000 per company. Asset Management often facilitates company
formation, to take advantage of opportunities in markets and technologies.
Franklin P. Johnson, Jr. , General Partner
Craig Taylor, General Partner
John F. Shoch, General Partner
W. Ferrell Sanders, General Partner
Douglas E. Kelly, M.D., General Partner
|
